新辅助化疗后乳腺病理完全缓解与腋窝病理完全缓解的关联性

doi:10.6040/j.issn.1671-7554.0.2017.1094

摘要/Abstract

摘要： 目的探讨新辅助化疗(NAC)后乳腺病理完全缓解(pCR)患者腋窝转移的风险及意义。方法回顾性连续收集2014年3月5日至2017年7月21日在河南省肿瘤医院乳腺科接受NAC的原发乳腺癌病例资料701例。采用χ2检验比较腋窝pCR(apCR)与临床病理特征及乳腺pCR(bpCR)的关系,应用Logistic回归分析各个变量与apCR的关联性。结果淋巴结分期、雌激素受体(ER)、人类表皮生长因子受体2(HER2)是apCR的独立预测因素。bpCR组中HER2阳性、cN0患者93%腋窝没有转移,基底样型(BL)、cN0组7例中的6例腋窝达到pCR,cN1组apCR率达67%;而在Luminal A&B型组患者中,cN0组apCR分别有3、17例(60%、40%),cN1组分别有8、20例(47%、27%)。未bpCR组NAC后腋窝转移风险比bpCR组高4.53倍。结论 NAC后bpCR与腋窝转移有高度关联性,HER2阳性的cN0/1患者和BL型cN0患者,NAC后如达到bpCR,其腋窝转移风险较低。

关键词: 乳腺癌, 新辅助化疗, 腋窝淋巴结, 病理完全缓解

Abstract: Objective To investigate the risk and significance of axillary metastasis in patients who achieved breast pathologic complete response(pCR)after neoadjuvant chemotherapy(NAC). Methods The clinical data of 701 breast cancer cases treated with NAC during 5th March 2014 and 21st July 2017 were retrospectively analyzed. The relationship of axillary pCR(apCR)with clinicopathological characteristics and breast pCR(bpCR)was calculated using χ2 test. The correlation between the variables and apCR was analyzed with multivariate binary logistic regression. Results Lymph node staging, estrogen receptor(ER)and HER2 were independent predictors for apCR. Among bpCR patients who were HER2 positive and cN0, 93% had no nodal metastasis(14/15), and 6 of 7 cases had an apCR in basal-like, cN0 group. The aPCR rate in the cN1 group were 67%. Among Luminal A&B groups, 3 and 17(60%, 40%)patients with cN0 disease, while 8 and 20(47%, 27%)patients with cN1 disease had an apCR. Compared with patients with bpCR, those without bpCR had 4.53 times higher risk of positive nodal metastases. Conclusion The nodal status is highly correlated with bpCR after neoadjuvant chemotherapy. Patients with cN0/1 who are HER2 positive and BL subtype patients with cN0 have low risk of nodal metastases if they achieve bpCR after neoadjuvant chemotherapy.

Key words: Breast cancer, Neoadjuvant chemotherapy, Axillary lymph node, Pathologic complete response

中图分类号:

R737.9

朱久俊,焦得闯,乔江华,王丽娜,马有钊,阳跃,卢振铎,刘真真. 新辅助化疗后乳腺病理完全缓解与腋窝病理完全缓解的关联性[J]. 山东大学学报 (医学版), 2018, 56(1): 32-37.

ZHU Jiujun, JIAO Dechuang, QIAO Jianghua, WANG Lina, MA Youzhao, YANG Yue, LU Zhenduo, LIU Zhenzhen. Correlation between breast and axillary pathologic complete response after neoadjuvant chemotherapy[J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 32-37.

参考文献

[1] Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from national surgical adjuvant breast and bowel project protocol b-27[J]. J Clin Oncol, 2005, 23(12): 2694-2702.
[2] Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with her2-positive locally advanced breast cancer(the noah trial): A randomised controlled superiority trial with a parallel her2-negative cohort[J]. Lancet, 2010, 375(9712): 377-384.
[3] Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen[J]. Clin Cancer Res, 2007, 13(1): 228-233.
[4] van la Parra RF, Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders: Historical perspective and current trials[J]. Breast Cancer Res, 2016, 18(1): 28.
[5] Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: A review[J]. JAMA Oncol, 2017, 3(4): 549-555.
[6] Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7th Edition[M]. New York: Springer, 2010.
[7] Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223.
[8] Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen receptor expression and outcomes in early breast cancer: A systematic review and meta-analysis[J]. J Natl Cancer Inst, 2014, 106(1): 319.
[9] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: The ctneobc pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
[10] Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy[J]. J Clin Oncol, 2005, 23(36): 9304-9311.
[11] Bayraktar S, Gonzalez-Angulo AM, Lei X, et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for her2-positive breast cancer[J]. Cancer, 2012, 118(9): 2385-2393.
[12] Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the techno trial of the ago and gbg study groups[J]. J Clin Oncol, 2011, 29(25): 3351-3357.
[13] Zhang GC, Zhang YF, Xu FP, et al. Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer[J]. Curr Oncol, 2013, 20(3): 180-192.
[14] Saxena N, Hartman M, Aziz R, et al. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study[J]. Eur J Cancer, 2011, 47(8): 1186-1192.
[15] Stoetzer OJ, Fersching DM, Salat C, et al. Circulating immunogenic cell death biomarkers hmgb1 and rage in breast cancer patients during neoadjuvant chemotherapy[J]. Tumour Biol, 2013, 34(1): 81-90.
[16] Ohno S, Chow LW, Sato N, et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil- epirubicin-cyclophosphamide(fec)in early-stage breast cancer: Exploratory analyses identify ki67 as a predictive biomarker for response to neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2013, 142(1): 69-80.
[17] Nwaogu IY, Fayanju OM, Jeffe DB, et al. Predictors of pathological complete response to neoadjuvant chemotherapy in stage ii and iii breast cancer: The impact of chemotherapeutic regimen[J]. Mol Clin Oncol, 2015, 3(5): 1117-1122.
[18] Kuerer HM, Rauch GM, Krishnamurthy S, et al. Abstract p5-16-30: Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy[J]. Cancer Research, 2017, 77(4 Supplement): P5-16-30.
[19] Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery[J]. JAMA Surg, 2017, 152(7): 665-670.

相关文章 15

[1]	林芸,谢燕秋. 乳腺癌患者生育力保护及保存[J]. 山东大学学报 (医学版), 2022, 60(9): 42-46.
[2]	贺士卿,李皖皖,董书晴,牟婧怡,刘宇莹,魏思雨,刘钊,张家新. 基于数据库构建乳腺癌焦亡相关基因的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(8): 34-43.
[3]	杨其峰,张宁. 精准医疗时代的乳腺癌前哨淋巴结活检[J]. 山东大学学报 (医学版), 2022, 60(8): 1-5.
[4]	赵婷婷,齐亚娜,张颖,袁冰,韩明勇. 小鼠乳腺癌诱导转移前肺组织微环境的改变[J]. 山东大学学报 (医学版), 2022, 60(4): 24-29.
[5]	初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139.
[6]	王喆,刘玉洁,毛倩,管佩霞,包绮晗,李承圣,乔晓伟,潘庆忠,王素珍. 基于逆概率加权法的早期三阴性乳腺癌不同治疗方案的疗效评价[J]. 山东大学学报 (医学版), 2021, 59(8): 113-118.
[7]	李皖皖,周文凯,董书晴,贺士卿,刘钊,张家新,刘斌. 利用数据库信息构建乳腺癌免疫关联lncRNAs风险评估模型[J]. 山东大学学报 (医学版), 2021, 59(7): 74-84.
[8]	孔雪,李娟,段伟丽,史爽,李培龙,杜鲁涛,毛海婷,王传新. 长链非编码RNA AC012073.1对乳腺癌细胞迁移侵袭的影响及临床价值[J]. 山东大学学报 (医学版), 2021, 59(4): 70-78.
[9]	高奎,万广宁,宋晓鹏,信波. 吡咯替尼治疗曲妥珠耐药HER2阳性乳腺癌1例[J]. 山东大学学报 (医学版), 2020, 58(12): 117-120.
[10]	陈波,张磊. 2017年乳腺癌新辅助治疗进展[J]. 山东大学学报 (医学版), 2018, 56(1): 12-16.
[11]	刘荫华,赵婧祎,辛灵. 美国临床肿瘤学会多基因检测临床实践指南更新及临床意义[J]. 山东大学学报 (医学版), 2018, 56(1): 1-5.
[12]	石爱平,徐格格,解新鹏. St.Gallen会议乳腺癌新辅助治疗回顾[J]. 山东大学学报 (医学版), 2018, 56(1): 6-11.
[13]	王殊,彭媛. 从2017年美国临床肿瘤学会大会报告看早期乳腺癌治疗加减法[J]. 山东大学学报 (医学版), 2018, 56(1): 17-21.
[14]	余之刚,王斐. 乳腺癌多基因检测的再思考:机遇与挑战[J]. 山东大学学报 (医学版), 2018, 56(1): 22-26.
[15]	凌瑞,张聚良. 乳腺癌内分泌治疗的相关进展[J]. 山东大学学报 (医学版), 2018, 56(1): 27-31.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed